Mylan

FDA Sends Warning Letter to EpiPen Manufacturer
FDA Sends Warning Letter to EpiPen ManufacturerEpiPen manufacturer is accused of lax investigation into problems.
Mylan Finalizes $465 Million EpiPen Settlement
Mylan Finalizes $465 Million EpiPen SettlementThe settlement is the end of a long legal battle.
FDA approves EpiPen rivalAdamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
Are EpiPens Still Good After Their Expiration Date?
Are EpiPens Still Good After Their Expiration Date?One pharmacist decided to find out how long an EpiPen stays useable.
EpiPen and EpiPen Jr. Recalled: Recall Expanded from Europe and AsiaTwo previous reports of device failures lead EpiPen maker to expand recall to the United States.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
EpiPens Recalled Overseas Due to Reported FailuresTwo device failures lead Mylan to recall more than 80,000 EpiPens overseas.
Generic versions of major depression drug availableMylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
Drug maker pays out millions over EpiPen chargesAs Mylan continues to face criticism over price hikes on its EpiPen epinephrine injection, the company agreed to a $465 million settlement with the U.S. Department of Justice and other agencies for overcharging on the EpiPen.